TScan Therapeutics, Inc. - TCRX STOCK NEWS

TScan Therapeutics, Inc. (TCRX) announced the appointment of Dr. Barbara Klencke to its Board of Directors, effective April 6, 2023. With over 20 years of oncology drug development experience, Dr. Klencke's expertise will enhance the company's clinical and commercial strategies as it advances its T cell receptor-engineered therapies for cancer. Key leadership promotions were also unveiled, with Shrikanta Chattopadhyay, Ann Hargraves, and Ray Lockard stepping up to Senior Vice President roles in Medical, Human Resources, and Technical Operations, respectively. These changes aim to strengthen TScan's operational capabilities and support ongoing clinical trials targeting hematologic malignancies and solid tumors throughout 2023.

TScan Therapeutics, Inc. (Nasdaq: TCRX) announced the appointment of Gavin MacBeath, Ph.D., as acting CEO, effective March 28, 2023, following the resignation of David Southwell. MacBeath, who has been with TScan since 2018 and has extensive experience in academia and industry, will continue to lead the company's clinical programs, including the recently dosed patient for TSC-101. TScan reports progress in clinical trials for hematologic malignancies and solid tumors, with plans for patient enrollment in the second quarter of 2023. As of December 31, 2022, the company had $120 million in cash, sufficient to fund operations into Q2 2024.

TScan Therapeutics has announced the successful dosing of the first patient in its Phase 1 clinical trial for TSC-101, aimed at treating leukemia and preventing relapse post-hematopoietic cell transplantation. This innovative therapy targets minor histocompatibility antigen HA-2 and is designed for patients with acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), or acute lymphocytic leukemia (ALL). The trial, which includes TSC-100 and TSC-101, strives to improve outcomes for patients undergoing reduced intensity conditioning (RIC) prior to transplantation, addressing a significant relapse rate of approximately 40% in this population.

TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company specializing in T cell receptor (TCR)-engineered therapies, has announced participation in the Barclays Global Healthcare Conference on March 15, 2023, at 4:05 p.m. Eastern Time. This event will take place at the Loews Miami Beach Hotel. A webcast will be accessible on their website’s 'Events and Presentations' section, with an archived replay available for 90 days post-event.

The company focuses on TCR-T therapies for cancer treatment, with lead candidates TSC-100 and TSC-101 targeting hematologic malignancies and additional therapies for solid tumors.

TScan Therapeutics (TCRX) announced its Phase 1 umbrella trial for TSC-100 and TSC-101 targeting hematologic malignancies is on track, with patient enrollment expected to complete mid-2023. The company received FDA clearance for multiple INDs, including T-Plex, facilitating the use of various TCRs in solid tumor trials. Financially, TScan ended 2022 with $120 million in cash, funding operations into Q2 2024. The company reported Q4 2022 revenue of $3.1 million, an increase from $2.9 million YoY, but incurred a net loss of $18.7 million, up from $14.2 million. Total revenue for 2022 stood at $13.5 million, compared to $10.1 million in 2021.

TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company, will participate in a panel discussion at the Cowen 43rd Annual Health Care Conference on March 8, 2023, at 2:10 p.m. ET in Boston, MA. The panel will focus on the development of T cell receptor (TCR)-engineered therapies for cancer treatment. A live webcast can be accessed through the Company’s website, with an archived replay available for 30 days post-event. TScan's lead candidates, TSC-100 and TSC-101, target hematologic malignancies while expanding their ImmunoBank for solid tumor therapies.

TScan Therapeutics (Nasdaq: TCRX), a biopharmaceutical company specializing in T cell receptor (TCR)-engineered T cell therapies, announced its participation in the H.C. Wainwright Cell Therapy Virtual Conference on February 28, 2023, at 3:30 p.m. Eastern Time. The presentation will be accessible via webcast on the Company’s website. TScan is developing lead therapy candidates TSC-100 and TSC-101 for treating hematologic malignancies, aiming to eliminate residual disease post-transplantation. Additionally, the company is building its ImmunoBank to provide customized therapies targeting various solid tumors.

TScan Therapeutics, Inc. (Nasdaq: TCRX) announced the FDA's clearance of its investigational new drug (IND) applications for its solid tumor program, T-Plex, along with two TCR-T products targeting MAGE-A1. T-Plex will facilitate customized combinations of TCR-T therapies, enabling personalized treatment based on tumor characteristics. The first two INDs target specific HLA types and are pivotal for advancing TScan's ImmunoBank. The company plans to initiate a multicenter Phase 1 clinical trial for various cancers by mid-2023, with initial results expected by year-end, marking significant progress in tailored cancer therapies.

TScan Therapeutics (TCRX) announced progress in its clinical pipeline, focusing on T cell receptor (TCR)-engineered therapies for cancer. The Phase 1 umbrella trial for treatments TSC-100 and TSC-101 is active across five sites, with expectations to enroll first cohorts in 1H 2023 and interim data due by year-end. The company has filed INDs for multiple TCRs targeting solid tumors and has sufficient cash to fund operations into Q2 2024. Leadership emphasized 2023 as a pivotal year, anticipating significant data readouts.